Ongoing study in PD patients: Assess safety and efficacy. Mean change from baseline to weeks 12 and 26 for the AAV-GAD groups compared to the sham group in MDS-UPDRS Part 3 score in the "off" state. Here, GAD1 is linked to Parkinson disease.